A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2016
At a glance
- Drugs DSM 265 (Primary)
- Indications Malaria
- Focus Adverse reactions; Pharmacokinetics
- 21 Aug 2015 According to the Australian New Zealand Clinical Trials Registry Record, status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Aug 2015 New trial record